News

Successfully passed the visit of the selection center to participate in the clinical trial for the treatment of systemic lupus erythematosus, the sponsor of the study is the pharmaceutical company Biogen

We continue to cooperate with the pharmaceutical company Pfizer: participation in a series of clinical trials of new IPs for the treatment of patients with ulcerative colitis has been proposed.

A selection visit was successfully completed to participate in a randomized, double-blind, placebo-controlled 24-week phase 3b study to eliminate moderate and severe vasomotor symptoms (hot flashes) in postmenopausal women for whom hormone replacement therapy is unacceptable.

A selection visit was successfully completed to participate in a phase III clinical trial for sublingual immunotherapy of tree pollen allergy for children from 5 to 17 years old.